Enjoy complimentary customisation on priority with our Enterprise License!
As per the Technavio’s market research report, the global anxiety and panic disorders drugs market is expected to grow at a steady rate and post a CAGR of close to 2% during the forecast period. The advancements in neurogenetics will drive the growth prospects for the global anxiety and panic disorders drugs market from 2017 to 2021. Scientific advancements such as genetic engineering and new DNA-editing technologies have enabled researchers to gain a better insight of the genes associated with the progression of anxiety disorders, which helps in the development of target therapies to treat them. The gene NTRK3 is responsible for causing panic disorder because the deregulation of this gene leads to malfunctioning of the fear-related memory system. The study of this gene under neurogenetics enables the researchers to come up with therapies that directly stimulate the affected area of the brain and produce pharmacological effects.
The synergistic effects of medication aided with neuromodulation devices are one of the key anxiety and panic disorders drugs market trends responsible for the market’s growth during the projected period. The neuromodulation is a novel psychiatric treatment and when it is taken along with the traditional therapeutic regimen, provides a complete treatment for anxiety and panic disorders, which will further boost the acceptance of these drugs in the market.
The global anxiety and panic disorders drugs market is highly fragmented due to the presence of a number of large and small players. These vendors are increasingly competing against each other due to factors such as emerging indications or applications, major patent expiries, and the rising prevalence of anxiety and panic disorder in the developed and other developing countries. Furthermore, some of these vendors are increasingly manufacturing a wide range of pharmaceutical products for various segments such as respiratory, inflammation and autoimmunity, cardiovascular and metabolic diseases, oncology, infection, neuroscience, and gastrointestinal.
Key vendors in this market are
Other prominent vendors in the market include Azevan Pharmaceuticals, Baxter, Bristol-Myers Squibb, and F. Hoffman-La Roche.
Based on the anxiety and panic disorders drugs market statistics, the anxiety and panic disorders antidepressant drugs segment contributed to the majority of the revenue to the overall market and will continue to be the major revenue contributor to the market during the next four years as well. The introduction of the newer selective serotonin reuptake inhibitor (SSRIs) with more safer side effects is driving the market segment’s growth in the coming years. Brintellix was approved by the US FDA in September 2013 for the treatment of depression.
According to this market research report, the Americas accounted for the majority market share during 2016 and will continue to dominate the market in the coming years. The rising number of visits to a psychiatrist and the increasing prevalence of the anxiety disorders in this region will accelerate the rate of revenue generation in the market.
Want a bigger picture? Try a FREE sample of this report now!
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Disease overview
PART 06: Pipeline analysis
PART 07: Market landscape
PART 08: Market segmentation by drug class
PART 09: Geographical segmentation
PART 10: Decision framework
PART 11: Drivers and challenges
PART 12: Market trends
PART 13: Vendor landscape
PART 14: Key vendor analysis
PART 15: Appendix
Tags: anxiety test, anxiety medication, heart valves, heart failure, healthcare market research, medical devices market research,
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.